United States of America based
Cotinga Pharmaceuticals (COT.V) (formerly “Critical Outcome Technologies Inc.”) is a biopharmaceutical company focused on developing treatments for a broad range of cancers by targeting the fundamental mechanisms driving cancer cell survival. We apply Cotinga’s proprietary technologies and oncology expertise to develop drug candidates that inhibit major mechanisms implicit in cancer cell survival and growth. Cotinga’s drug candidates have demonstrated the ability to target key pathways and prevent cancer cells from thriving and replicating. We are advancing our lead product candidate, COTI-2, to address difficult-to-treat cancers, such as ovarian cancer and head and neck squamous cell carcinoma, while building a robust pipeline for a wide range of additional cancers.
Our passion for making a meaningful difference in the lives of people living with cancer is at the core of everything we do; from our technology to our product candidates and most importantly, our people.
TechnologiesAI Companies (Drug Discovery)
CHEMSAS® is a multi-staged computational platform technology based upon a hybrid of machine learning technologies and proprietary algorithms that allows prediction of biological activity from molecular structures. COTI-2 and COTI-219 are the first compounds derived with the benefit of CHEMSAS to be developed by Cotinga.
ROSALIND™ is a simulation platform designed to provide better personalized treatment options based on the genetic profile of the patient’s cancer.
COTI-2, targeting p-53
Cotinga Pharma has the potential to reach a broad spectrum of cancers by targeting key cancer mechanisms, such as p53 and KRAS, with our two most advanced product candidate
COTI-219, targeting KRAS
Cotinga Pharma has the potential to reach a broad spectrum of cancers by targeting key cancer mechanisms, such as p53 and KRAS, with our two most advanced product candidates.
No services posted yet